David Dai
About David Dai
David Dai is the Senior Director of Strategic Pricing at BeiGene in the San Francisco Bay Area, with over 20 years of experience in the biotechnology and pharmaceutical industries, specializing in strategic pricing and market access within the oncology sector.
Company
David Dai is currently employed at BeiGene, a biotechnology company specializing in the development and commercialization of innovative cancer therapies. He operates out of the San Francisco Bay Area, where he holds the role of Senior Director, Strategic Pricing.
Title
David Dai serves as the Senior Director of Strategic Pricing at BeiGene. His role focuses on developing and executing pricing strategies for the company’s oncology products, ensuring competitive positioning in the market.
Education and Expertise
David Dai holds an MBA in Marketing and Finance from The Wharton School, completed from 1998 to 2000. He also has an MSc in Development Studies (Economics) from the University of Bath, completed from 1987 to 1988, and a Bachelor of Arts in English from the University of International Relations, completed from 1982 to 1986. His expertise spans strategic pricing, market access, managed markets, and reimbursement strategies within the biotech and pharmaceutical industries.
Professional Background
David Dai has over 20 years of experience in the biotechnology and pharmaceutical industries. He has held various leadership roles, including Director, Market Access at Clovis Oncology (2015-2019), Associate Director, Managed Markets at Biogen Idec (2012-2015), Associate Director, OCG at Sunovion Pharmaceuticals Inc. (2010-2012), Senior Director, Pricing, Access, and Reimbursement Strategy at bioTheranostics (2008-2010), Segment Manager, Managed Care at Roche Pharmaceuticals (2006-2008), Marketing Professional, Brand Strategy and Managed Care at Eli Lilly (2001-2006), and Management Consultant at The Boston Consulting Group (2000-2001).
Achievements
David Dai has a proven track record of developing and implementing successful pricing strategies for biotech products. His strategic insights have contributed to market access and reimbursement strategies that ensure the commercial success of oncology treatments.